Pfizer outlines 2025 R&D milestones and oncology growth opportunities

Earnings Call Insights: Pfizer (NYSE:PFE) Q4 2024

Management View

• CEO Albert Bourla highlighted Pfizer’s strong execution in 2024, emphasizing the successful integration of Seagen, which has positioned Pfizer as a leading oncology company. He noted, “We met or exceeded our goals for 2024 while